Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Clinical trial NCT02318784 · COMPLETED

Trial details

NCT number: NCT02318784
Sponsor: SCRI Development Innovations, LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Cancer

Start date: 2015-07-15
Primary completion: 2021-05-15
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.